吡格列酮
医学
炎症
过氧化物酶体增殖物激活受体
动脉瘤
内科学
受体
兴奋剂
巨噬细胞
内分泌学
外科
糖尿病
生物
体外
2型糖尿病
生物化学
作者
Kenji Shimada,Hajime Furukawa,Kosuke Wada,Masaaki Korai,Yuan Wei,Yoshiteru Tada,Atsushi Kuwabara,Fumiaki Shikata,Keiko T. Kitazato,Shinji Nagahiro,Michael T. Lawton,Tomoki Hashimoto
出处
期刊:Stroke
[Lippincott Williams & Wilkins]
日期:2015-05-01
卷期号:46 (6): 1664-1672
被引量:75
标识
DOI:10.1161/strokeaha.114.007722
摘要
Background and Purpose— Inflammation is emerging as a key component of the pathophysiology of intracranial aneurysms. Peroxisome proliferator–activated receptor-γ (PPARγ) is a nuclear hormone receptor of which activation modulates various aspects of inflammation. Methods— Using a mouse model of intracranial aneurysm, we examined the potential roles of PPARγ in the development of rupture of intracranial aneurysm. Results— A PPARγ agonist, pioglitazone, significantly reduced the incidence of ruptured aneurysms and the rupture rate without affecting the total incidence aneurysm (unruptured aneurysms and ruptured aneurysms). PPARγ antagonist (GW9662) abolished the protective effect of pioglitazone. The protective effect of pioglitazone was absent in mice lacking macrophage PPARγ. Pioglitazone treatment reduced the mRNA levels of inflammatory cytokines (monocyte chemoattractant factor-1, interleukin-1, and interleukin-6) that are primarily produced by macrophages in the cerebral arteries. Pioglitazone treatment reduced the infiltration of M1 macrophage into the cerebral arteries and the macrophage M1/M2 ratio. Depletion of macrophages significantly reduced the rupture rate. Conclusions— Our data showed that the activation of macrophage PPARγ protects against the development of aneurysmal rupture. PPARγ in inflammatory cells may be a potential therapeutic target for the prevention of aneurysmal rupture.
科研通智能强力驱动
Strongly Powered by AbleSci AI